Research programme: ion channel modulators - Merck

Drug Profile

Research programme: ion channel modulators - Merck

Alternative Names: A 317567 analogues - Merck; A-1048400; A-317567; A-803467; Ion channel modulators - Abbott/Icagen

Latest Information Update: 13 Feb 2013

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Abbott Laboratories; Icagen
  • Developer Abbott Laboratories; Icagen; Merck & Co
  • Class Aniline compounds; Furans; Isoquinolines; Naphthalenes; Small molecules
  • Mechanism of Action Ion channel modulators; Sodium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Inflammation; Pain
  • Discontinued Genitourinary disorders; Neurogenic bladder; Neuropathic pain

Most Recent Events

  • 13 Feb 2013 No development reported - Preclinical for Inflammation in USA (PO)
  • 13 Feb 2013 No development reported - Preclinical for Pain in USA (PO)
  • 31 Dec 2012 Discontinued - Preclinical for Neuropathic pain in USA (PO) before December 2012
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top